Biofronter’s drug device combination therapy uses Ameluz, a photosensitising agent and porphyrin precursor, in combination with a BF-RhodoLED lamp to administer PDT therapy and kill cancerous and precancerous cells. Image credit: eamesBot / Shutterstock.

Biofrontera has announced topline results from a Phase III trial evaluating its drug-device therapy, Ameluz gel and photodynamic therapy (PDT) with BF-RhodoLED lamp, as a treatment for superficial basal cell carcinoma (sBCC).

The drug-device combination met the primary composite endpoint of complete clinical and histological clearance of one preselected “main target” BCC lesion per patient 12 weeks after the start of the last PDT cycle, with Ameluz-PDT treatment achieving 65.5% success, compared to 4.8% success seen in the placebo-PDT group.

“Once we finish the one-year follow-up phase in December, we will be in a position to submit our dossier to the US Food and Drug Administration (FDA) around the end of Q2 / early Q3 of 2025,” said Dr Hermann Luebbert, CEO and Chairman of the Massachusetts-based company.

Following the announcement, Biofrontera’s stock was up to  $1.23 at market close yesterday (31 October), a 31.71% rise compared to the market open on the same day. 

The Phase III trial (NCT03573401) enrolled 187 participants with sBCC. Complete histological clearance of lesions was seen in 75.9% of the participants treated with Ameluz-PDT, compared to 19% in the placebo arm. Furthermore, complete clinical clearance was seen in 83.4% of participants in Ameluz-PDT arm, compared to 21.4% who received placebo-PDT treatment.

The trial also met the secondary endpoint with 64.1% of Ameluz-PDT patients achieving total clearance of all sBCC lesions compared to only 4.8% of those treated with placebo-PDT. Additionally, 64.3% of patients in the Ameluz-PDT arm rated the overall treatment satisfaction and aesthetic outcome as very good, with 22.2% rating it as good.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Ameluz PDT therapy uses Ameluz, a photosensitising agent and porphyrin precursor, in combination with a BF-RhodoLED lamp to administer PDT therapy and kill cancerous and precancerous cells. In the US, the Ameluz PDT therapy is approved to treat mild to moderate actinic keratoses on the face and scalp.

PDT therapy is also being evaluated for eye disorders. A US-based company PhotoPharmics  is investigating its Celeste phototherapy device as a functional treatment for Parkinson’s disease.